Management of Abdominal Pain in Functional Constipation

Introduction to Treatment Approaches

The American Gastroenterological Association recommends starting with soluble fiber (ispaghula/psyllium 3-4 g/day, gradually increased) and antispasmodics for abdominal pain associated with functional constipation, then escalating to low-dose tricyclic antidepressants (amitriptyline 10 mg nightly, titrated to 30-50 mg) if pain persists despite adequate treatment of constipation 1

The European Society of Gastroenterology recommends regular physical exercise to all patients as foundational therapy, which improves global symptoms and should be the cornerstone of treatment 1
Soluble fiber (ispaghula/psyllium) should be started at 3-4 g/day, building up gradually to avoid worsening bloating and gas, which is effective for both global symptoms and abdominal pain 1
Insoluble fiber (wheat bran) should be avoided as it consistently worsens symptoms in functional constipation patients 1

Polyethylene glycol (PEG) should be used as the osmotic laxative of choice, titrating the dose according to symptoms, with abdominal pain being the most common side effect 1
If PEG fails after 4-6 weeks, bisacodyl 10-15 mg daily should be added as a stimulant laxative, with a goal of one non-forced bowel movement every 1-2 days 1

Antispasmodics are effective for abdominal pain, particularly when symptoms are exacerbated by meals, though dry mouth, visual disturbance, and dizziness are common side effects 1, 3
Peppermint oil can be effective for global symptoms and abdominal pain, though gastroesophageal reflux is a common side effect 4, 3

Tricyclic antidepressants (TCAs) are the most effective second-line treatment for abdominal pain and global symptoms in functional constipation, with amitriptyline started at 10 mg once daily at bedtime, titrated slowly to 30-50 mg daily based on symptomatic response 5, 1
TCAs should be continued for at least 6 months if the patient reports symptomatic response, then attempt gradual withdrawal 1
TCAs should be used cautiously in functional constipation and ensure adequate laxative therapy is in place, as TCAs may worsen constipation through anticholinergic effects 1

Linaclotide 290 mcg once daily on an empty stomach is the preferred prescription agent, with high-quality evidence supporting its use for both constipation and abdominal pain 1
Linaclotide has visceral analgesic activity through its action on guanylate cyclase-C, generating cyclic GMP which stimulates chloride secretion and may reduce pain perception 4

Cognitive-behavioral therapy specific for IBS and gut-directed hypnotherapy should be considered when symptoms persist despite 12 months of pharmacological treatment, particularly effective when symptoms significantly impair quality of life or when there are associated psychological disorders 5, 1, 3

Anticholinergic antispasmodics (dicyclomine, hyoscyamine) should not be prescribed in functional constipation, as they will worsen the constipation through reduced motility and enhanced water reabsorption 1
IgG antibody-based food elimination diets or gluten-free diets should not be recommended unless celiac disease is confirmed, as evidence does not support their use 1, 3
Docusate (Colace) should not be continued as it lacks efficacy for constipation and should be stopped immediately 1
Opioids should not be used for chronic abdominal pain management in functional constipation due to risks of dependence, complications, and worsening constipation 4
Managing patient expectations is crucial, as complete symptom resolution is often not achievable; the goal is symptom relief and improved quality of life 1, 3